Evrofarma Dividends and Buybacks

Dividend criteria checks 3/6

Evrofarma is a dividend paying company with a current yield of 2.69% that is well covered by earnings.

Key information

2.7%

Dividend yield

n/a

Buyback Yield

Total Shareholder Yieldn/a
Future Dividend Yieldn/a
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per share€0.050
Payout ratio31%

Recent dividend and buyback updates

Recent updates

A Piece Of The Puzzle Missing From Evrofarma SA's (ATH:EVROF) Share Price

Dec 19
A Piece Of The Puzzle Missing From Evrofarma SA's (ATH:EVROF) Share Price

Earnings Troubles May Signal Larger Issues for Evrofarma (ATH:EVROF) Shareholders

Oct 02
Earnings Troubles May Signal Larger Issues for Evrofarma (ATH:EVROF) Shareholders

Subdued Growth No Barrier To Evrofarma SA (ATH:EVROF) With Shares Advancing 30%

Feb 29
Subdued Growth No Barrier To Evrofarma SA (ATH:EVROF) With Shares Advancing 30%

Evrofarma SA (ATH:EVROF) Stock Rockets 33% But Many Are Still Ignoring The Company

Jan 06
Evrofarma SA (ATH:EVROF) Stock Rockets 33% But Many Are Still Ignoring The Company

Returns On Capital At Evrofarma (ATH:EVROF) Have Stalled

Jan 05
Returns On Capital At Evrofarma (ATH:EVROF) Have Stalled

Evrofarma (ATH:EVROF) Has A Somewhat Strained Balance Sheet

Dec 01
Evrofarma (ATH:EVROF) Has A Somewhat Strained Balance Sheet

Here's What's Concerning About Evrofarma's (ATH:EVROF) Returns On Capital

Sep 15
Here's What's Concerning About Evrofarma's (ATH:EVROF) Returns On Capital

Is Evrofarma (ATH:EVROF) Using Too Much Debt?

May 27
Is Evrofarma (ATH:EVROF) Using Too Much Debt?

We Think That There Are Issues Underlying Evrofarma's (ATH:EVROF) Earnings

Oct 04
We Think That There Are Issues Underlying Evrofarma's (ATH:EVROF) Earnings

Returns On Capital At Evrofarma (ATH:EVROF) Paint A Concerning Picture

May 19
Returns On Capital At Evrofarma (ATH:EVROF) Paint A Concerning Picture

Should Evrofarma SA (ATH:EVROF) Focus On Improving This Fundamental Metric?

Feb 22
Should Evrofarma SA (ATH:EVROF) Focus On Improving This Fundamental Metric?

Be Wary Of Evrofarma (ATH:EVROF) And Its Returns On Capital

Dec 29
Be Wary Of Evrofarma (ATH:EVROF) And Its Returns On Capital

Is Evrofarma SA's (ATH:EVROF) 2.2% ROE Worse Than Average?

Nov 22
Is Evrofarma SA's (ATH:EVROF) 2.2% ROE Worse Than Average?

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Too early to tell whether EVROF's dividend payments have been stable as they only just started paying a dividend.

Growing Dividend: Too early to tell if EVROF's dividend payments are increasing as they only just started paying a dividend.


Dividend Yield vs Market

Evrofarma Dividend Yield vs Market
How does EVROF dividend yield compare to the market?
SegmentDividend Yield
Company (EVROF)2.7%
Market Bottom 25% (GR)1.9%
Market Top 25% (GR)5.1%
Industry Average (Food)3.5%
Analyst forecast (EVROF) (up to 3 years)n/a

Notable Dividend: EVROF's dividend (2.69%) is higher than the bottom 25% of dividend payers in the Greek market (1.95%).

High Dividend: EVROF's dividend (2.69%) is low compared to the top 25% of dividend payers in the Greek market (5.08%).


Earnings Payout to Shareholders

Earnings Coverage: With its reasonably low payout ratio (31.3%), EVROF's dividend payments are well covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: With its reasonably low cash payout ratio (28.2%), EVROF's dividend payments are well covered by cash flows.


Discover strong dividend paying companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/20 13:14
End of Day Share Price 2025/01/17 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Evrofarma SA is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution